Geptanolimab clinical trials
Also written GB226, APL-501 and genolimzumab.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses geptanolimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Genor Biopharma Co., Ltd. (7) · Apollomics (Australia) Pty. Ltd. (2)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses geptanolimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsCompletedPhase 1Apollomics (Australia) Pty. Ltd.NCT03053466Written as APL-501
- APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCCTerminatedPhase 1/2Apollomics (Australia) Pty. Ltd.NCT03655613Written as APL-501
- Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/LymphomaStatus unknownPhase 1Genor Biopharma Co., Ltd.NCT03374007Written as Geptanolimab Injection 1mg/kg
- Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)Status unknownPhase 2Genor Biopharma Co., Ltd.NCT03502629Written as GB226
- A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 PositiveStatus unknownPhase 2Genor Biopharma Co., Ltd.NCT03808857Written as GB226
- Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)Status unknownPhase 2Genor Biopharma Co., Ltd.NCT03639181Written as GB226
- Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)Status unknownPhase 2Genor Biopharma Co., Ltd.NCT03623581Written as GB226
- Safety and Efficacy of Genolimzumab (GB226) in Combination With FruquintinibStatus unknownPhase 1Genor Biopharma Co., Ltd.NCT03976856Written as GB226
- Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal CancerStatus unknownPhase 1Genor Biopharma Co., Ltd.NCT03977090Written as Geptanolimab Injection
Codes
What other systems call geptanolimab · ClinicalTrials.gg INT016573
- UNII (FDA) FME52R2SGNGEPTANOLIMABOne source FDA
- NCI Thesaurus C148159GeptanolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FME52R2SGN | GEPTANOLIMAB | One source FDA |
| NCI Thesaurus | C148159 | Geptanolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.